GeoVax Labs, Inc. (GOVX) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] GeoVax Labs Inc (GOVX) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, GeoVax is a tiny clinical-stage biotech trying to turn vaccine programs—especially its mpox/smallpox candidate GEO-MVA—into a real commercial business, but right now it’s still mostly a high-risk development story rather than an established operating company. > **📍 Basic Profile** > > Market Cap **$7.68 million** · Biotechnology · NASDAQ NMS - GLOBAL MARKET · Price **$2.21** > **⚡ 3 Things You Should Know** > > 1. 💉 Binary biotech setup: The whole story is heavily tied to GEO-MVA and the planned Phase 3 start in the second half of the year—if execution goes well, the stock can re-rate fast, but if timelines slip, the downside can also be brutal. > > 2. ⚠️ The finances are weak even by biotech standards: margins are deeply negative, cash flow is negative, and the company recently used a warrant inducement transaction, which usually tells you funding is still a live issue and dilution risk is real. > > 3. 📈 The stock is trading like a speculation vehicle, not a stable business: beta is very high, the shares just had an almost 80% one-day jump, yet they still sit far below the 52-week high—basically, sentiment can swing much faster than fundamentals here. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin -403.8%, gross margin -31.76% | > | Growth Rate | Fast🚀 | 3-year revenue growth 212.58%, but from a very small base | > | Financial Health | Moderate💛 | Debt ratio 0%, current ratio 2.74, but cash flow remains negative | > | Valuation | [Data unavailable] | PE not meaningful because earnings are negative | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** GeoVax develops vaccines and immunotherapies for infectious disease and cancer, aiming to make money through eventual product commercialization, partnerships, licensing, and possible government or procurement-related demand. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Vaccine / immunotherapy development programs | [Data unavailable] | ↑ | The value is concentrated in pipeline progress rather than diversified revenue streams | | Other / collaboration-related revenue | [Data unavailable] | → | Revenue exists, but current data does not show a stable recurring commercial base | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | -31.76% | Below Average | This suggests current revenue is not covering core cost of revenue, which is common for very early-stage biotech names but still a red flag for business maturity | | Net Margin | -403.8% | Below Average | In other words, the company is burning far more than it brings in | | ROE | -441.4% | Below Average | Extremely negative returns reflect ongoing losses and a very thin equity base | --- #### 📈 How's the Growth? **Growth Assessment:** High Growth, but low-quality and highly volatile | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Latest annual figure unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Quality:** > What’s interesting is the headline 3-year revenue growth number looks huge at 212.58%, but for a micro-cap clinical-stage biotech, that can be misleading because growth often comes from a tiny base, milestone timing, grants, or accounting lumpiness rather than a scalable commercial engine. Basically, this is not the kind of growth you’d treat like a normal software or consumer company. --- #### 💰 Financial Health Check **One Sentence:** Think of it like a startup with no mortgage and decent short-term liquidity, but no steady paycheck—so it may still need to raise more money to keep going. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 0% debt-to-equity | <60% safe | ✅Safe | | Current Ratio | 2.74 | >1.5 healthy | ✅Safe | | Cash Flow | Negative ($-0.896 per share TTM) | >0 | 🚨Negative | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $0.9631 - 52-Week High: $34.75 - Current: $2.21, Near the low | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(3.7% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE [Data unavailable] | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | P/S 1.25x | Industry avg [Data unavailable] | Hard to judge without comparable pipeline-stage peer set | **What the Current Valuation is Betting On:** > The current price looks depressed versus the 52-week high, but that does not automatically mean “cheap.” In biotech, a low price often means the market is discounting financing risk, execution risk, and the possibility that pipeline assets never become profitable products. So what the market seems to be betting on is simple: GEO-MVA must keep hitting milestones, and the company must survive long enough financially to reach them. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-05-17 | Stock mentioned among major movers; shares surged sharply in session | Neutral + More about trading momentum than a change in intrinsic value | | 2026-05-13 | Q1 EPS of $(2.62) beat estimate of $(4.42) | Mild Positive + Better-than-feared losses help sentiment, though the company is still unprofitable | | 2026-04-15 | Reported year-end results and said pivotal Phase 3 trial for GEO-MVA is planned for 2H 2026 | Positive + This is the key operating catalyst the whole story revolves around | | 2026-04-14 | Highlighted GEO-MVA as a potential answer to mpox/smallpox vaccine supply constraints | Positive + Reinforces the commercial narrative if the product gets through development | | 2026-03-31 | Announced warrant inducement transaction | Negative + Usually a sign the company is leaning on capital markets, which can increase dilution risk | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | -31.76% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -403.8% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -441.4% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | ↑ | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2026-03-31 | $-4.51 | $-2.62 | +41.89% Beat 😀 | | 2025-12-31 | $-6.29 | $-0.01 | +99.92% Beat 😀 | | 2025-09-30 | $-6.76 | $-7.75 | -14.69% Miss 😟 | | 2025-06-30 | $-9.18 | $-8.75 | +4.68% Beat 😀 | **Earnings Trend Interpretation:** Three beats in the last four quarters tell you expectations had gotten very low and management has done better than feared on reported losses. But worth noting, “beating” while still losing money is not the same as having a healthy business model—it mainly buys time and supports sentiment. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 8 firms | 80% | | Hold | 2 firms | 20% | | Sell | 0 firms | 0% | **Target Price:** [Data unavailable] **vs Current Price:** [Data unavailable] **Insider Activity:** Net [Data unavailable] in past 3 months > No insider transaction data was provided here, so there’s no clean signal to read from management trading activity. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Clinical execution risk:** GEO-MVA’s Phase 3 timeline is central to the thesis → If the trial start is delayed or data disappoints, the stock could lose momentum quickly. 2. **Financing / dilution risk:** Negative cash flow and recent warrant inducement activity suggest future capital raises are possible → If this happens, existing shareholders may be diluted. 3. **Extreme volatility risk:** With beta at 3.58 and a very small market cap, trading can become detached from fundamentals → If sentiment reverses, the stock can swing down just as violently as it swings up. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** GeoVax is a micro-cap clinical-stage biotech built around vaccine development, with GEO-MVA now the main thing driving the story. > > **Key strength:** The company has a live catalyst path ahead, no balance-sheet debt, and recent earnings came in less bad than expected, which gives it some room to keep the narrative going. > > **Key risk:** The business is still deeply loss-making, funding risk is very real, and for a stock this small, share price moves can be driven more by speculation than fundamentals. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis